Case report: Iatrogenic Kaposi sarcoma secondary to Janus kinase and tumor necrosis factor‐alpha inhibitors in rheumatoid arthritis

Saved in:
Bibliographic Details
Published in:International journal of rheumatic diseases 2024-10, Vol.27 (10), p.e15365-n/a
Main Authors: Garza‐Elizondo, Angel Kevin, Oscherwitz, Max, Cervantes‐Ramirez, Valeria, Salazar‐Marentes, Enrique, Galarza‐Delgado, Dionicio Angel, Cardenas‐de la Garza, Jesus Alberto
Format: Article
Language:English
Subjects:
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Female
Humans
Iatrogenic Disease
Janus kinase
Janus Kinase Inhibitors - adverse effects
Janus Kinase Inhibitors - therapeutic use
Male
Middle Aged
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Rheumatoid arthritis
Sarcoma
Sarcoma, Kaposi - chemically induced
Sarcoma, Kaposi - drug therapy
Treatment Outcome
Tumor Necrosis Factor Inhibitors - adverse effects
Tumor Necrosis Factor Inhibitors - therapeutic use
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c2555-2e95d9d999ea2697dd061472607b2adff0b714b406dcee5fa57a8cc58bb90f7a3
container_end_page n/a
container_issue 10
container_start_page e15365
container_title International journal of rheumatic diseases
container_volume 27
creator Garza‐Elizondo, Angel Kevin
Oscherwitz, Max
Cervantes‐Ramirez, Valeria
Salazar‐Marentes, Enrique
Galarza‐Delgado, Dionicio Angel
Cardenas‐de la Garza, Jesus Alberto
description
doi_str_mv 10.1111/1756-185X.15365
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3113752812</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3113752812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2555-2e95d9d999ea2697dd061472607b2adff0b714b406dcee5fa57a8cc58bb90f7a3</originalsourceid><addsrcrecordid>eNqFkT-P1DAQxS0E4o6Dmg5ZoqHZOzuJ45jutOLPwUpQgERnTewJ6yOxg-0IXUdDz2fkk-CwxxY0TDOj0e89efwIeczZOS91waVoN7wTn865qFtxh5weN3ePc8NPyIOUrhlred3K--SkVrWsWSdOyY8tJKQR5xDzc3oFOYbP6J2hb2EOydEE0YQJaEITvIV4Q3Ogb8AviX5xftWCtzQvU4jUo4lFk-gAJof46_tPGOc9UOf3rndlk8pI4x6XCXJwlkLM--iySw_JvQHGhI9u-xn5-PLFh-3rze7dq6vt5W5jKiHEpkIlrLJKKYSqVdLaclEjq5bJvgI7DKyXvOkb1lqDKAYQEjpjRNf3ig0S6jPy7OA7x_B1wZT15JLBcQSPYUm65ryWoup4VdCn_6DXYYm-vK5QFWtU1zSyUBcHar08RRz0HN1UvklzpteE9JqBXvPQfxIqiie3vks_oT3yfyMpgDgA39yIN__z05fvdwfj3yGHnmg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3120498447</pqid></control><display><type>article</type><title>Case report: Iatrogenic Kaposi sarcoma secondary to Janus kinase and tumor necrosis factor‐alpha inhibitors in rheumatoid arthritis</title><source>Wiley</source><creator>Garza‐Elizondo, Angel Kevin ; Oscherwitz, Max ; Cervantes‐Ramirez, Valeria ; Salazar‐Marentes, Enrique ; Galarza‐Delgado, Dionicio Angel ; Cardenas‐de la Garza, Jesus Alberto</creator><creatorcontrib>Garza‐Elizondo, Angel Kevin ; Oscherwitz, Max ; Cervantes‐Ramirez, Valeria ; Salazar‐Marentes, Enrique ; Galarza‐Delgado, Dionicio Angel ; Cardenas‐de la Garza, Jesus Alberto</creatorcontrib><identifier>ISSN: 1756-1841</identifier><identifier>ISSN: 1756-185X</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/1756-185X.15365</identifier><identifier>PMID: 39373085</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Female ; Humans ; Iatrogenic Disease ; Janus kinase ; Janus Kinase Inhibitors - adverse effects ; Janus Kinase Inhibitors - therapeutic use ; Male ; Middle Aged ; Pyrazoles - adverse effects ; Pyrazoles - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Rheumatoid arthritis ; Sarcoma ; Sarcoma, Kaposi - chemically induced ; Sarcoma, Kaposi - drug therapy ; Treatment Outcome ; Tumor Necrosis Factor Inhibitors - adverse effects ; Tumor Necrosis Factor Inhibitors - therapeutic use ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><ispartof>International journal of rheumatic diseases, 2024-10, Vol.27 (10), p.e15365-n/a</ispartof><rights>2024 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</rights><rights>International Journal of Rheumatic Diseases © 2024 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2555-2e95d9d999ea2697dd061472607b2adff0b714b406dcee5fa57a8cc58bb90f7a3</cites><orcidid>0000-0002-5099-0079 ; 0000-0001-9714-2109 ; 0000-0003-4572-5032 ; 0009-0008-2281-9451 ; 0009-0004-7546-0463 ; 0009-0008-2162-7896</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39373085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garza‐Elizondo, Angel Kevin</creatorcontrib><creatorcontrib>Oscherwitz, Max</creatorcontrib><creatorcontrib>Cervantes‐Ramirez, Valeria</creatorcontrib><creatorcontrib>Salazar‐Marentes, Enrique</creatorcontrib><creatorcontrib>Galarza‐Delgado, Dionicio Angel</creatorcontrib><creatorcontrib>Cardenas‐de la Garza, Jesus Alberto</creatorcontrib><title>Case report: Iatrogenic Kaposi sarcoma secondary to Janus kinase and tumor necrosis factor‐alpha inhibitors in rheumatoid arthritis</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Iatrogenic Disease</subject><subject>Janus kinase</subject><subject>Janus Kinase Inhibitors - adverse effects</subject><subject>Janus Kinase Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Rheumatoid arthritis</subject><subject>Sarcoma</subject><subject>Sarcoma, Kaposi - chemically induced</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Treatment Outcome</subject><subject>Tumor Necrosis Factor Inhibitors - adverse effects</subject><subject>Tumor Necrosis Factor Inhibitors - therapeutic use</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><issn>1756-1841</issn><issn>1756-185X</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkT-P1DAQxS0E4o6Dmg5ZoqHZOzuJ45jutOLPwUpQgERnTewJ6yOxg-0IXUdDz2fkk-CwxxY0TDOj0e89efwIeczZOS91waVoN7wTn865qFtxh5weN3ePc8NPyIOUrhlred3K--SkVrWsWSdOyY8tJKQR5xDzc3oFOYbP6J2hb2EOydEE0YQJaEITvIV4Q3Ogb8AviX5xftWCtzQvU4jUo4lFk-gAJof46_tPGOc9UOf3rndlk8pI4x6XCXJwlkLM--iySw_JvQHGhI9u-xn5-PLFh-3rze7dq6vt5W5jKiHEpkIlrLJKKYSqVdLaclEjq5bJvgI7DKyXvOkb1lqDKAYQEjpjRNf3ig0S6jPy7OA7x_B1wZT15JLBcQSPYUm65ryWoup4VdCn_6DXYYm-vK5QFWtU1zSyUBcHar08RRz0HN1UvklzpteE9JqBXvPQfxIqiie3vks_oT3yfyMpgDgA39yIN__z05fvdwfj3yGHnmg</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Garza‐Elizondo, Angel Kevin</creator><creator>Oscherwitz, Max</creator><creator>Cervantes‐Ramirez, Valeria</creator><creator>Salazar‐Marentes, Enrique</creator><creator>Galarza‐Delgado, Dionicio Angel</creator><creator>Cardenas‐de la Garza, Jesus Alberto</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5099-0079</orcidid><orcidid>https://orcid.org/0000-0001-9714-2109</orcidid><orcidid>https://orcid.org/0000-0003-4572-5032</orcidid><orcidid>https://orcid.org/0009-0008-2281-9451</orcidid><orcidid>https://orcid.org/0009-0004-7546-0463</orcidid><orcidid>https://orcid.org/0009-0008-2162-7896</orcidid></search><sort><creationdate>202410</creationdate><title>Case report: Iatrogenic Kaposi sarcoma secondary to Janus kinase and tumor necrosis factor‐alpha inhibitors in rheumatoid arthritis</title><author>Garza‐Elizondo, Angel Kevin ; Oscherwitz, Max ; Cervantes‐Ramirez, Valeria ; Salazar‐Marentes, Enrique ; Galarza‐Delgado, Dionicio Angel ; Cardenas‐de la Garza, Jesus Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2555-2e95d9d999ea2697dd061472607b2adff0b714b406dcee5fa57a8cc58bb90f7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Iatrogenic Disease</topic><topic>Janus kinase</topic><topic>Janus Kinase Inhibitors - adverse effects</topic><topic>Janus Kinase Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Rheumatoid arthritis</topic><topic>Sarcoma</topic><topic>Sarcoma, Kaposi - chemically induced</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Treatment Outcome</topic><topic>Tumor Necrosis Factor Inhibitors - adverse effects</topic><topic>Tumor Necrosis Factor Inhibitors - therapeutic use</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garza‐Elizondo, Angel Kevin</creatorcontrib><creatorcontrib>Oscherwitz, Max</creatorcontrib><creatorcontrib>Cervantes‐Ramirez, Valeria</creatorcontrib><creatorcontrib>Salazar‐Marentes, Enrique</creatorcontrib><creatorcontrib>Galarza‐Delgado, Dionicio Angel</creatorcontrib><creatorcontrib>Cardenas‐de la Garza, Jesus Alberto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garza‐Elizondo, Angel Kevin</au><au>Oscherwitz, Max</au><au>Cervantes‐Ramirez, Valeria</au><au>Salazar‐Marentes, Enrique</au><au>Galarza‐Delgado, Dionicio Angel</au><au>Cardenas‐de la Garza, Jesus Alberto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Case report: Iatrogenic Kaposi sarcoma secondary to Janus kinase and tumor necrosis factor‐alpha inhibitors in rheumatoid arthritis</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2024-10</date><risdate>2024</risdate><volume>27</volume><issue>10</issue><spage>e15365</spage><epage>n/a</epage><pages>e15365-n/a</pages><issn>1756-1841</issn><issn>1756-185X</issn><eissn>1756-185X</eissn><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39373085</pmid><doi>10.1111/1756-185X.15365</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-5099-0079</orcidid><orcidid>https://orcid.org/0000-0001-9714-2109</orcidid><orcidid>https://orcid.org/0000-0003-4572-5032</orcidid><orcidid>https://orcid.org/0009-0008-2281-9451</orcidid><orcidid>https://orcid.org/0009-0004-7546-0463</orcidid><orcidid>https://orcid.org/0009-0008-2162-7896</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1756-1841
ispartof International journal of rheumatic diseases, 2024-10, Vol.27 (10), p.e15365-n/a
issn 1756-1841
1756-185X
1756-185X
language eng
recordid cdi_proquest_miscellaneous_3113752812
source Wiley
subjects Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Arthritis, Rheumatoid - drug therapy
Female
Humans
Iatrogenic Disease
Janus kinase
Janus Kinase Inhibitors - adverse effects
Janus Kinase Inhibitors - therapeutic use
Male
Middle Aged
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Rheumatoid arthritis
Sarcoma
Sarcoma, Kaposi - chemically induced
Sarcoma, Kaposi - drug therapy
Treatment Outcome
Tumor Necrosis Factor Inhibitors - adverse effects
Tumor Necrosis Factor Inhibitors - therapeutic use
Tumor Necrosis Factor-alpha - antagonists & inhibitors
title Case report: Iatrogenic Kaposi sarcoma secondary to Janus kinase and tumor necrosis factor‐alpha inhibitors in rheumatoid arthritis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A27%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Case%20report:%20Iatrogenic%20Kaposi%20sarcoma%20secondary%20to%20Janus%20kinase%20and%20tumor%20necrosis%20factor%E2%80%90alpha%20inhibitors%20in%20rheumatoid%20arthritis&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=Garza%E2%80%90Elizondo,%20Angel%20Kevin&rft.date=2024-10&rft.volume=27&rft.issue=10&rft.spage=e15365&rft.epage=n/a&rft.pages=e15365-n/a&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/1756-185X.15365&rft_dat=%3Cproquest_cross%3E3113752812%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2555-2e95d9d999ea2697dd061472607b2adff0b714b406dcee5fa57a8cc58bb90f7a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3120498447&rft_id=info:pmid/39373085&rfr_iscdi=true